The present invention relates generally to implantable medical devices including rechargeable power sources. More specifically, the present invention pertains to methods, systems, and apparatus for recharging medical devices implanted within the body.
Actively powered implantable medical devices sometimes require a power supply such as a battery or power capacitor to provide electrical power to the device, in some cases over an extended period of time. In cardiac rhythm management applications, for example, an implantable medical device such as a pressure sensor may require a power supply capable of operating the device over a period of several years. In some cases, the time required to power the device is beyond the capability of the power supply, requiring replacement of the power supply or the implantation of a new device within the body.
With advances in power management and battery technology, more recent trends have focused on the use of small rechargeable power sources for providing power to implantable devices. Current charging techniques often rely on the patient and/or a health-care provider to ensure that the battery is charged periodically. In some cases, the patient may be required to undergo recharging within a clinical environment, which can be burdensome to the patient and often adds to the overall costs associated with recharging. If recharging is to be performed in a clinic, for example, a special area may be required for the patient while the recharging is being performed, adding to the overall cost and time associated with the maintenance.
The present invention pertains to methods, systems, and apparatus for recharging medical devices implanted within the body. An illustrative recharging system includes a device implanted within the body having a rechargeable power source and a receiver, and a charging device adapted to provide charging energy to the implanted device from a location within the body adjacent to the device. A charging element coupled to the charging device is configured to transmit energy at a location within the body proximate to the receiver. In some embodiments, for example, the charging element includes a source transducer adapted to transmit an acoustic signal to a target transducer coupled to the implanted device for acoustically recharging the device. Alternatively, and in other embodiments, the charging element includes an electromagnetic transmitter adapted to transmit an electromagnetic signal to an antenna or coil coupled to the implanted device for recharging the device using RF or other forms of electromagnetic energy. Other energy transfer modes can also be employed for recharging the implanted device.
An illustrative method of recharging a medical device implanted within a body lumen of a patient's body includes delivering a distal section of the charging device to a location adjacent to the implanted device, activating a charging element operatively coupled to a power source and wirelessly transmitting energy to a receiver coupled to the implanted device, and converting the energy received by the receiver into electrical energy for charging the implanted device. The charging device can be positioned at a target location within the same body lumen as the implanted device, or alternatively, within a different body lumen. For recharging a pressure sensor implanted within a pulmonary artery, for example, the charging device can be delivered to a location within the pulmonary artery, an adjacent artery, or an adjacent lumen or cavity such as the aorta or esophagus. Once positioned adjacent to the implanted device, the charging element can be activated to transmit charging energy to the device from a position within the body. In some embodiments, the charging device can be used to perform other functions within the body such as calibrating the implanted device, confirming the proper operation of the charging device, and/or performing therapy within the body.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
The charging catheter 14 includes an elongate shaft 32 having a proximal section 34 located outside of the patient's body, and a distal section 36 insertable into the patient's body at a location adjacent to the implanted device 12. In the illustrative embodiment of
In some embodiments, the charging catheter 14 can be inserted into the main pulmonary artery 26 via an intravenous approach from a percutaneous access site such as a femoral artery or jugular vein. As shown in
The implanted device 12 can be configured to perform one or more designated functions, including the sensing of physiological parameters within the body and/or providing therapy to the patient. Example physiological parameters that can be sensed using the implanted device 12 include, but are not limited to, blood pressure, blood or fluid flow, temperature, and strain. Various electrical, chemical, and/or magnetic properties may also be sensed within the body using the implanted device 12. The specific configuration and function to be performed by the implanted device 12 will typically vary depending on the particular therapeutic needs of the patient.
In some embodiments, the implanted device 12 comprises a pressure sensor adapted to sense arterial blood pressure within a pulmonary artery. As shown in the illustrative system 10 of
The implanted device 12 can be used as part of a cardiac rhythm management (CRM) system to predict decompensation of a heart failure patient, to optimize pacing and/or defibrillation therapy, as well as perform other designated functions within the body. In certain embodiments, for example, the implanted device 12 can be configured to transmit sensed physiological parameters to other CRM system components located within the body such as a pacemaker or defibrillator. In some embodiments, the implanted device 12 can be configured to transmit sensed physiological parameters to an external device such as a monitor or programmer for further monitoring and/or processing. Based on this information, an indication of any abnormalities within the heart 16 can be determined and an appropriate therapy provided to the patient, as necessary.
During recharging, the power source 50 can be configured to deliver a time-varying excitation current to the ultrasonic transducer 48, causing the transducer 48 to generate an acoustic signal 56 within the body that is received by a receiver 58 coupled to the implanted device 12. In some embodiments, for example, the receiver 58 comprises an ultrasonic transducer sensitive to the frequency of the acoustic signal 56 transmitted from the source ultrasonic transducer 48. The acoustic signal 56 received by the target ultrasonic transducer 58 is then converted into electrical energy that can be used to recharge the battery 46.
During delivery, the source ultrasonic transducer 48 on the charging catheter 14 can be positioned in close proximity to the target ultrasonic transducer 58 of the implanted device 12. In certain embodiments, for example, the distal section 36 of the charging catheter 14 can be positioned such that the source ultrasonic transducer 48 is located a distance of between about 1 mm to about 10 mm apart from the target ultrasonic transducer 58. The distance at which the two transducers 48,58 are spaced apart from each other may be greater or lesser, however, depending on the type of transducers 48,58 employed, the intensity and frequency characteristics of the acoustic signal 56 transmitted, the anatomy surrounding the transducers 48,58, as well as other factors. In some embodiments, the positioning of the charging catheter 14 can be accomplished under the aid of fluoroscopy. A radiopaque marker band 60 placed at or near the distal end of the charging catheter 14 can be used in conjunction with a fluoroscope to visualize the location of the charging catheter 14 during delivery so as to minimize the distance between the transducers 48,58.
Once the distal section 36 of the charging catheter 14 is positioned at a target location within the body adjacent to the implanted device 12, the ultrasonic transducer 48 can be activated to transmit an acoustic signal 56 to the implanted device 12 for recharging the battery 46 in vivo. The time required to deliver a sufficient amount of charging energy to recharge the battery 46 may be affected by several factors, including the location of the device 12 within the body, the location of the charging catheter 14 within the body, the distance between the source and target ultrasonic transducers 48,58, and the intensity and frequency of the acoustic signal 56. Typically, the acoustic intensity of the acoustic signal 56 falls off inversely proportional to the square of the distance from the ultrasonic transducer 48. Thus, for a given flux of energy, there is an initial rapid decrease in intensity in the near field followed by a more gradual decline further away from the transducer 48.
By placing the source and target transducers 48,58 in close proximity to each other, the attenuation loss associated with the rapid fall off of acoustic energy in the near field is reduced, resulting in an increase in charge coupling efficiency. This increase in efficiency reduces the overall time required to recharge the battery 46, and subjects the body to less energy than would otherwise be required to recharge the battery 46 via an external recharging approach with the source ultrasonic transducer transmitting the charging energy directly into the body. This results in a higher intensity field in the vicinity of the implanted device 12 while maintaining a lower overall energy flux transmitted into the body. In addition, because the source transducer 48 is located in close proximity to the target transducer 58, a smaller portion of the transmitted acoustic energy is absorbed and/or scattered within the body, resulting in more efficient charging with reduced body tissue and fluid heating.
Although the illustrative charging catheter 14 of
In some embodiments, the charging catheter 14 further includes a focusing or collimating element adapted to direct and focus the charging energy transmitted to the implanted device 12. In those embodiments in which the charging element 44 includes an ultrasonic transducer 48, for example, the charging element 44 may further include an acoustic baffle or lens for focusing the acoustic signal 56 in the direction of the target transducer 58. In some embodiments, focusing of the acoustic signal 56 may occur by selectively activating one or more ultrasonic transducer elements within a transducer array, by adjusting the timing or phase of one or more ultrasonic transducer elements, and/or by adjusting the intensity levels of one or more ultrasonic transducer elements. Other techniques for focusing the transmitted acoustic signal 56 are also possible.
In certain embodiments, the charging element 44 is configured to provide charging energy to the implanted device 12 by directly contacting a surface on the device 12. In one such embodiment, for example, the charging element 44 includes an electrode adapted to electrically contact a corresponding electrode on the implanted device 12. During delivery, the distal section 36 of the charging catheter 14 can be positioned within the body such that the two electrodes make electrical contact with each other. Once positioned, the electrode on the charging catheter 14 can be energized, causing current to flow to the electrode on the implanted device 12. As with other energy transmission modes discussed herein, the charging energy received by the implanted device 12 can then be used to recharge the battery 46.
In some embodiments, and as further shown in
In certain embodiments, the sensor 78 is a temperature sensor 78 adapted to measure the temperature of body tissue and/or the local blood temperature at or near the location of the implanted device 12. In some embodiments, for example, the temperature sensor 78 can be configured to sense the local blood temperature of blood in the path of the acoustic signal 76, which can be used to estimate the temperature of the body tissue adjacent to the implanted device 12. The charging catheter 64 can be positioned within the vessel such that the temperature sensor 78 contacts the body tissue within the vessel, allowing the sensor 78 to directly sense the body tissue temperature adjacent to the implanted device 12. Based on the monitored temperature, the system can then either reduce the power of the acoustic energy transmitted by the ultrasonic transducer(s) 70, or alternatively, disable one or more of the transducers 70 in the event the temperature exceeds a maximum temperature threshold value. The monitored temperature can also be provided as feedback to notify a clinician of a potentially hazardous condition related to the operation of the charging catheter 64. The temperature sensor 78 can also be utilized to perform other tasks such as calibrating the charging element 68.
In some embodiments, the sensor 78 can be configured to monitor for the presence of any electrical leakage from the charging element 68. For example, the sensor 78 can comprise a sensor adapted to detect the presence of any current leakage from the ultrasonic transducer(s) 70 into the surround anatomy. The monitoring of electrical leakage from the ultrasonic transducers 70 can be accomplished, for example, by measuring the current into and out of the transducers 70 using a differential current transformer, a bridge circuit, or the like. If an electrical leakage is detected, and depending on its magnitude, the system can then either adjust the operating power provided to one or more of the ultrasonic transducers 70 or disable the transducers 70 in order to reduce or eliminate the electrical leakage. This may be useful, for example, in acoustic charging systems that deliver relatively high voltages to the transducer elements. The charging system can also be configured to notify the clinician if a fault condition has occurred in the charging catheter 64.
The implanted device 12 can be further configured to monitor a number of parameters associated with the acoustic signal 76 received from the charging catheter 64. For example, in those embodiments in which the implanted device 12 includes an energy exchanger (e.g., an ultrasonic transducer), the implanted device 12 can be configured to monitor the power or intensity of the acoustic signal 76 transmitted by the charging catheter 64 to determine whether the signal 76 is within an acceptable range. If the received acoustic signal 76 exceeds a maximum power or intensity value, for example, the implanted device 12 can be configured to communicate a signal back to the charging catheter 64, which can be used by the catheter 64 as feedback to adjust the intensity or power of the signal 76. In some embodiments, the feedback signal can also be used by the clinician to aid in repositioning the charging catheter 64 within the vessel to maximize the charge coupling efficiency between the catheter 64 and the implanted device 12. In one embodiment, for example, the feedback signal can be used to adjust the placement location of charging catheter 64, and in particular the location of the charging element 68 within the vessel, in order to optimize the charging energy received by the implanted device 12.
In some embodiments, and as further shown in
In use, the thermocouple wire 94 can be configured to sense temperature at the distal section 82 of the charging catheter 84, which can then be used to estimate the temperature of the body tissue and/or blood in the path of the acoustic signal 88. In some embodiments, an exposed portion 100 of the thermocouple wire 96 may permit the wire 96 to sense the local temperature within the blood vessel or, if placed into contact with the vessel wall, the body tissue temperature. The exposed portion 100 of the thermocouple wire 96 can also be used to sense other parameters within the vessel. In certain embodiments, for example, the exposed portion 100 of the thermocouple wire 96 may also function as a voltimeter probe to detect the presence of any electrical leakage from the charging element 86 by measuring electrical potentials within the vessel.
In another embodiment, the thermocouple wire 96 can be coupled directly to the charging element 86 for monitoring the temperature of the element 86 itself. For an acoustic recharging system including an ultrasonic transducer 90, for example, the thermocouple wire 96 can be attached to a portion of the transducer 90 to monitor the temperature of the transducer 90 during recharging. Since heating in the vessel is due in part to heat conduction from the ultrasonic transducer 90, the temperature within the vessel can be monitored indirectly using the thermocouple wire 96. The sensed temperature on the ultrasonic transducer 70 can then be used as feedback for regulating the operating power provided to the transducer 70.
In some embodiments, an additional lumen 114 can be used as a return line to return the cooling medium 110 back to the proximal section of the charging catheter 104 once heated. During recharging, the cooling medium 110 can be circulated through the interior of the distal section 102 to dissipate the heat generated by the charging element 112 and to reduce heating of the body tissue and fluids surrounding the catheter 104. In some embodiments, the temperature of the cooling medium 110 can be reduced to a temperature below room temperature to further aid in dissipating heat generated by the charging element 112.
During recharging, the presence of the cooling medium 110 within the lumens 108,114 facilitates operation of the charging element 112 at higher intensity levels without causing significant heating in the surrounding body tissue and fluids. When the charging catheter 104 is implanted in a pulmonary artery, for example, the presence of the cooling medium 110 facilitates operation of the charging element 112 at greater intensity levels without heating the blood within the artery. The ability to operate at higher intensity levels without heating may reduce the overall time required to recharge the battery within the implanted device.
During recharging, a pressurized cooling medium 110 (e.g., saline) contained within the lumens 122,124 is ejected through the port 126 and into the surrounding anatomy. In recharging applications where the catheter 118 is positioned in a pulmonary artery adjacent to an implanted pressure sensor, for example, the cooling medium 110 may be ejected through the exit port 126 and into the artery for cooling the blood within the artery as well as the pressure sensor. As with the embodiment of
By positioning the charging catheter 132 into a different vessel than the implanted device 12, access to a target site for recharging may be easier and/or may be less invasive than inserting the catheter 132 directly into the same vessel as the device 12. In some cases, for example, the implanted device 12 may be implanted within a body lumen that is difficult to access. In such case, delivery of the charging catheter 132 to a different vessel within the body (e.g., the aorta, the right pulmonary artery, the esophagus, etc.) may reduce the overall time and difficulty associated with the recharging process.
Once the charging catheter 132 is positioned at a target location within an adjacent body lumen (e.g., the aorta 138), a charging element 140 coupled to the catheter 132 can be activated to transmit charging energy into the adjacent vessel (e.g., the left pulmonary artery 30) for recharging the implanted device 12. In those embodiments in which the charging element 140 includes an ultrasonic transducer 142, for example, the transducer 142 can be configured to transmit an acoustic signal 144 that can be received by the implanted device 12 and converted into electrical energy for recharging the device 12.
In some embodiments, the charging catheter 132 can be used to perform other functions within the body and/or to provide therapy to the patient. In certain embodiments, for example, the charging catheter 132 may be used during a diagnostic or therapeutic coronary artery catheterization (e.g., a right heart catheterization) for treating coronary artery disease within the body. In one such embodiment, the charging element 140 may be provided as part of a coronary balloon catheter for performing an angioplasty procedure on the patient. In such case, recharging of the implanted device 12 may be performed in conjunction with the therapy using the same catheterization.
The charging catheter 148 includes an elongate shaft 158 having an interior lumen 160 adapted to transmit charging energy generated by the charging element 152 from a location outside of the patient to the distal section 150 of the charging catheter 148. In some embodiments, for example, the charging element 152 comprises an external ultrasonic transducer that, when energized by the power source 156, generates an acoustic signal 162 that is transmitted through the interior lumen 160 to the distal section 150 of the catheter 148. In some embodiments, the ultrasonic transducer 152 comprises an array of ultrasonic transducer elements each of which can be selectively actuated to generate the acoustic signal 162. During recharging, the interior lumen 160 acts as an acoustic waveguide for the acoustic signal 162, reducing attenuation and scattering that would normally occur during transmission of the signal 162 directly through the body. Because the charging element 152 is located outside of the patient's body, the transducer 152 can be of any size and power without significantly impacting the acoustic energy transmitted into the body.
In some embodiments, the charging catheter 148 may include other components for use in focusing the charging energy generated by the charging element 152, either passively or actively. In the embodiment of
Alternatively, and in other embodiments, the distal section 150 of the charging catheter 148 may include a passive element such as a reflector or an active element such as a repeater adapted to generate a signal 172 that is received by an array of transducer elements. In certain embodiments, for example, the reflected or repeated signal may serve as a reference signal for a time-reversal acoustic algorithm that can be used to generate time reversals on one or more of the transducer elements in order to focus the acoustic signal 162 towards the implanted device 12. The sensor 168 on the charging catheter 148 can be configured to sense an acoustic signal transmitted by the implanted device 12. The sensed acoustic signal can then be transmitted to the external controller 170 for computing phase delays for each of the transducer elements. The external controller 170 can then adjust one or more parameters associated with the ultrasonic elements to focus or steer the acoustic signal 162 towards the implanted device 12. Example parameters that can be adjusted include, but are not limited to, direction, focusing, phase, intensity, timing, and/or bandwidth.
The sensor 168 can be used to perform other functions within the body such as calibrating the implanted device 12. In those embodiments in which the implanted device 12 comprises a pressure sensor, for example, the sensor 168 may be used as a reference pressure sensor to calibrate the device 12. In one embodiment, the reference pressure sensor and charging element can be combined into a single catheter. The ability to calibrate the implanted device 12 without subjecting the patient to an additional catheterization process may reduce the time and complexity associated with servicing the implanted device 12.
As can be further understood in conjunction with
The external controller 196 can include a signal generator 198 and a tuning circuit 200 that can be used to tune the frequency of the acoustic signal generated by the ultrasonic transducers 194 to a particular frequency or range of frequencies based on the resonance characteristics of the ultrasonic transducer elements used to transmit and receive the acoustic charging energy. In certain embodiments, for example, the signal generator 198 and tuning circuit 200 can be used to tune the ultrasonic transducer elements to a frequency of about 40 kHz, which can correspond to a resonance frequency of the ultrasonic transducer on the implanted device 12. In some embodiments, the signal generator 198 and tuning circuit 200 can be used to tune the ultrasonic transducer elements to operate over a desired range of frequencies (e.g., between about 10 kHz to 200 kHz). Other operating frequencies and frequency ranges are possible, however.
To recharge an implanted device 12 positioned in or near the heart 16, the distal section 190 of the charging device 176 can be inserted into the patient's esophagus 178 and advanced to a position within the esophagus 178 adjacent to the implantation location of the device 12. In those embodiments in which the implanted device 12 is located within a pulmonary artery 30, for example, the distal section 190 of the charging device 176 can be inserted into the esophagus 178 and positioned such that the charging element 192 is located in the mediastinum immediately posterior to the artery 30, as shown, for example, in
Once the charging device 176 is positioned within the esophagus 178 adjacent to the body vessel or lumen containing the implanted device 12, the charging element 192 can be activated to generate an acoustic signal that travels through the esophageal wall. As can be further seen in a transverse view of the patient's thorax in
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
This application is a continuation of U.S. application Ser. No. 12/605,579, filed Oct. 26, 2009, which claims priority under 35 U.S.C. §119 to U.S. Provisional Application No. 61/108,635, filed on Oct. 27, 2008, entitled “Methods and Systems for Recharging Implantable Devices,” all of which are incorporated herein by reference in their entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
2463533 | Harrison | Mar 1949 | A |
2786899 | Carlisle et al. | Mar 1957 | A |
3536836 | Pfeiffer | Oct 1970 | A |
3672352 | Summers | Jun 1972 | A |
3757770 | Brayshaw et al. | Sep 1973 | A |
3805796 | Terry, Jr. et al. | Apr 1974 | A |
3853117 | Murr | Dec 1974 | A |
3943915 | Severson | Mar 1976 | A |
3970987 | Kolm | Jul 1976 | A |
4026276 | Chubbuck | May 1977 | A |
4041954 | Ohara | Aug 1977 | A |
4062354 | Taylor et al. | Dec 1977 | A |
4082097 | Mann et al. | Apr 1978 | A |
4099530 | Chen et al. | Jul 1978 | A |
4127110 | Bullara | Nov 1978 | A |
4170742 | Itagaki et al. | Oct 1979 | A |
4206761 | Cosman | Jun 1980 | A |
4206762 | Cosman | Jun 1980 | A |
4265252 | Chubbuck et al. | May 1981 | A |
4281666 | Cosman | Aug 1981 | A |
4281667 | Cosman | Aug 1981 | A |
4340038 | McKean | Jul 1982 | A |
4354506 | Sakaguchi et al. | Oct 1982 | A |
4361153 | Slocum et al. | Nov 1982 | A |
4378809 | Cosman | Apr 1983 | A |
4385636 | Cosman | May 1983 | A |
4407296 | Anderson | Oct 1983 | A |
4471786 | Inagaki et al. | Sep 1984 | A |
4481950 | Duggan | Nov 1984 | A |
4494950 | Fischell | Jan 1985 | A |
4519401 | Ko et al. | May 1985 | A |
4556061 | Barreras et al. | Dec 1985 | A |
4593703 | Cosman | Jun 1986 | A |
4596255 | Snell et al. | Jun 1986 | A |
4614192 | Imran et al. | Sep 1986 | A |
4616640 | Kaali et al. | Oct 1986 | A |
4651740 | Schroeppel | Mar 1987 | A |
4653508 | Cosman | Mar 1987 | A |
4660568 | Cosman | Apr 1987 | A |
4676255 | Cosman | Jun 1987 | A |
4677985 | Bro et al. | Jul 1987 | A |
4708127 | Abdelghani | Nov 1987 | A |
4719919 | Moran et al. | Jan 1988 | A |
4791915 | Barsotti et al. | Dec 1988 | A |
4791936 | Snell et al. | Dec 1988 | A |
4793825 | Benjamin et al. | Dec 1988 | A |
4869251 | Lekholm et al. | Sep 1989 | A |
4885002 | Watanabe et al. | Dec 1989 | A |
4886065 | Collins, Jr. | Dec 1989 | A |
4911217 | Dunn et al. | Mar 1990 | A |
4918736 | Bordewijk | Apr 1990 | A |
5074310 | Mick | Dec 1991 | A |
5113859 | Funke | May 1992 | A |
5117835 | Mick | Jun 1992 | A |
5160870 | Carson et al. | Nov 1992 | A |
5168869 | Chirife | Dec 1992 | A |
5184605 | Grzeszykowski | Feb 1993 | A |
5218861 | Brown et al. | Jun 1993 | A |
5279292 | Baumann et al. | Jan 1994 | A |
5291899 | Watanabe et al. | Mar 1994 | A |
5381067 | Greenstein et al. | Jan 1995 | A |
5423334 | Jordan | Jun 1995 | A |
5433736 | Nilsson | Jul 1995 | A |
5438554 | Seyed-Bolorforosh et al. | Aug 1995 | A |
5445150 | Dumoulin et al. | Aug 1995 | A |
5495453 | Wociechowski et al. | Feb 1996 | A |
5562621 | Claude et al. | Oct 1996 | A |
5619997 | Kaplan | Apr 1997 | A |
5620475 | Magnusson | Apr 1997 | A |
5704352 | Tremblay et al. | Jan 1998 | A |
5704366 | Tacklind et al. | Jan 1998 | A |
5712917 | Offutt | Jan 1998 | A |
5721886 | Miller | Feb 1998 | A |
5724985 | Snell et al. | Mar 1998 | A |
5733249 | Katzin et al. | Mar 1998 | A |
5743267 | Nikolic et al. | Apr 1998 | A |
5749909 | Schroeppel et al. | May 1998 | A |
5757104 | Getman et al. | May 1998 | A |
5759199 | Snell et al. | Jun 1998 | A |
5776168 | Gunderson | Jul 1998 | A |
5800478 | Chen et al. | Sep 1998 | A |
5807258 | Cimochowski et al. | Sep 1998 | A |
5814089 | Stokes et al. | Sep 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5861018 | Feierbach | Jan 1999 | A |
5876353 | Riff | Mar 1999 | A |
5891180 | Greeninger et al. | Apr 1999 | A |
5904708 | Goedeke | May 1999 | A |
5925001 | Hoyt et al. | Jul 1999 | A |
5935078 | Feierbach | Aug 1999 | A |
5957861 | Combs et al. | Sep 1999 | A |
5967989 | Cimochowski et al. | Oct 1999 | A |
6015387 | Schwartz et al. | Jan 2000 | A |
6030374 | McDaniel | Feb 2000 | A |
6070103 | Ogden | May 2000 | A |
6140740 | Porat et al. | Oct 2000 | A |
6141588 | Cox et al. | Oct 2000 | A |
6162238 | Kaplan et al. | Dec 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6167303 | Thompson | Dec 2000 | A |
6170488 | Spillman, Jr. et al. | Jan 2001 | B1 |
6176840 | Nishimura et al. | Jan 2001 | B1 |
6183426 | Akisada et al. | Feb 2001 | B1 |
6185452 | Schulman et al. | Feb 2001 | B1 |
6185454 | Thompson | Feb 2001 | B1 |
6185460 | Thompson | Feb 2001 | B1 |
6198963 | Haim et al. | Mar 2001 | B1 |
6198965 | Penner et al. | Mar 2001 | B1 |
6198971 | Leysieffer | Mar 2001 | B1 |
6200265 | Walsh et al. | Mar 2001 | B1 |
6236889 | Soykan et al. | May 2001 | B1 |
6237398 | Porat et al. | May 2001 | B1 |
6248080 | Miesel et al. | Jun 2001 | B1 |
6259951 | Kuzma et al. | Jul 2001 | B1 |
6260152 | Cole et al. | Jul 2001 | B1 |
6261249 | Tallish et al. | Jul 2001 | B1 |
6277078 | Porat et al. | Aug 2001 | B1 |
6315721 | Schulman et al. | Nov 2001 | B2 |
6427088 | Bowman et al. | Jul 2002 | B1 |
6431175 | Penner et al. | Aug 2002 | B1 |
6432050 | Porat et al. | Aug 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6442433 | Linberg | Aug 2002 | B1 |
6472991 | Schulman et al. | Oct 2002 | B1 |
6473638 | Ferek-Petric | Oct 2002 | B2 |
6564807 | Schulman et al. | May 2003 | B1 |
6577899 | Lebel et al. | Jun 2003 | B2 |
6584352 | Combs et al. | Jun 2003 | B2 |
6607485 | Bardy | Aug 2003 | B2 |
6628989 | Penner et al. | Sep 2003 | B1 |
6644322 | Webb | Nov 2003 | B2 |
6664763 | Echarri et al. | Dec 2003 | B2 |
6671552 | Merritt et al. | Dec 2003 | B2 |
6676601 | Lacoste et al. | Jan 2004 | B1 |
6689091 | Bui et al. | Feb 2004 | B2 |
6712772 | Cohen et al. | Mar 2004 | B2 |
6731976 | Penn et al. | May 2004 | B2 |
6735532 | Freed et al. | May 2004 | B2 |
6754538 | Linberg | Jun 2004 | B2 |
6764446 | Wolinsky et al. | Jul 2004 | B2 |
6788973 | Davis et al. | Sep 2004 | B2 |
6790187 | Thompson et al. | Sep 2004 | B2 |
6799280 | Edenfield et al. | Sep 2004 | B1 |
6804557 | Kroll | Oct 2004 | B1 |
6826430 | Faltys et al. | Nov 2004 | B2 |
6855115 | Fonseca et al. | Feb 2005 | B2 |
6873869 | Fischer | Mar 2005 | B2 |
6960801 | Lung | Nov 2005 | B2 |
6970037 | Sakhuja et al. | Nov 2005 | B2 |
6978181 | Snell | Dec 2005 | B1 |
6985088 | Goetz et al. | Jan 2006 | B2 |
6985773 | Von Arx et al. | Jan 2006 | B2 |
6988215 | Splett et al. | Jan 2006 | B2 |
6993393 | Von Arx et al. | Jan 2006 | B2 |
7003349 | Andersson et al. | Feb 2006 | B1 |
7013178 | Reinke et al. | Mar 2006 | B2 |
7024248 | Penner et al. | Apr 2006 | B2 |
7027871 | Burnes et al. | Apr 2006 | B2 |
7027872 | Thompson | Apr 2006 | B2 |
7035684 | Lee | Apr 2006 | B2 |
7060030 | Von Arx et al. | Jun 2006 | B2 |
7061381 | Forcier et al. | Jun 2006 | B2 |
7082334 | Boute et al. | Jul 2006 | B2 |
7096068 | Mass et al. | Aug 2006 | B2 |
7123964 | Betzold et al. | Oct 2006 | B2 |
7198603 | Penner et al. | Apr 2007 | B2 |
7203551 | Houben et al. | Apr 2007 | B2 |
7209790 | Thompson et al. | Apr 2007 | B2 |
7212133 | Goetz et al. | May 2007 | B2 |
7236821 | Cates et al. | Jun 2007 | B2 |
7273457 | Penner et al. | Sep 2007 | B2 |
7283874 | Penner et al. | Oct 2007 | B2 |
7286872 | Kramer et al. | Oct 2007 | B2 |
7319903 | Bange et al. | Jan 2008 | B2 |
7335161 | Von Arx et al. | Feb 2008 | B2 |
7353063 | Simms, Jr. | Apr 2008 | B2 |
7469161 | Gandhi et al. | Dec 2008 | B1 |
7479108 | Rini et al. | Jan 2009 | B2 |
7617001 | Penner et al. | Nov 2009 | B2 |
7650185 | Maile et al. | Jan 2010 | B2 |
7756587 | Penner et al. | Jul 2010 | B2 |
7930031 | Penner | Apr 2011 | B2 |
RE42378 | Wolinsky et al. | May 2011 | E |
8078278 | Penner | Dec 2011 | B2 |
8271093 | Von Arx et al. | Sep 2012 | B2 |
8340776 | Doron et al. | Dec 2012 | B2 |
8374693 | Chavan et al. | Feb 2013 | B2 |
8577460 | Penner | Nov 2013 | B2 |
8593107 | Penner et al. | Nov 2013 | B2 |
20010025139 | Pearlman | Sep 2001 | A1 |
20020065540 | Lebel et al. | May 2002 | A1 |
20020077673 | Penner et al. | Jun 2002 | A1 |
20020151770 | Noll, III et al. | Oct 2002 | A1 |
20020169584 | Fu et al. | Nov 2002 | A1 |
20030114897 | Von Arx et al. | Jun 2003 | A1 |
20030212441 | Starkweather et al. | Nov 2003 | A1 |
20040039424 | Merritt et al. | Feb 2004 | A1 |
20040133092 | Kain | Jul 2004 | A1 |
20040152999 | Cohen et al. | Aug 2004 | A1 |
20040172083 | Penner | Sep 2004 | A1 |
20040210141 | Miller | Oct 2004 | A1 |
20050109338 | Stahmann et al. | May 2005 | A1 |
20050113705 | Fischell et al. | May 2005 | A1 |
20050136385 | Mann et al. | Jun 2005 | A1 |
20050159785 | Rueter | Jul 2005 | A1 |
20050159789 | Brockway et al. | Jul 2005 | A1 |
20050177135 | Hildebrand et al. | Aug 2005 | A1 |
20050182387 | Webler | Aug 2005 | A1 |
20050203444 | Schonenberger et al. | Sep 2005 | A1 |
20050265999 | Bush et al. | Dec 2005 | A1 |
20050288727 | Penner | Dec 2005 | A1 |
20060009818 | Von Arx et al. | Jan 2006 | A1 |
20060020307 | Davis et al. | Jan 2006 | A1 |
20060025834 | Von Arx et al. | Feb 2006 | A1 |
20060031378 | Vallapureddy et al. | Feb 2006 | A1 |
20060041287 | Dewing et al. | Feb 2006 | A1 |
20060041288 | Dewing et al. | Feb 2006 | A1 |
20060058627 | Flaherty et al. | Mar 2006 | A1 |
20060064134 | Mazar et al. | Mar 2006 | A1 |
20060064135 | Brockway | Mar 2006 | A1 |
20060064142 | Chavan et al. | Mar 2006 | A1 |
20060085039 | Hastings et al. | Apr 2006 | A1 |
20060094967 | Bennett et al. | May 2006 | A1 |
20060122667 | Chavan et al. | Jun 2006 | A1 |
20060142819 | Penner et al. | Jun 2006 | A1 |
20060149329 | Penner | Jul 2006 | A1 |
20070010742 | Torp et al. | Jan 2007 | A1 |
20070055317 | Stahmann et al. | Mar 2007 | A1 |
20070142728 | Penner et al. | Jun 2007 | A1 |
20070150014 | Kramer et al. | Jun 2007 | A1 |
20070162090 | Penner | Jul 2007 | A1 |
20070179549 | Russie | Aug 2007 | A1 |
20070250126 | Maile et al. | Oct 2007 | A1 |
20080015421 | Penner | Jan 2008 | A1 |
20080071178 | Greenland et al. | Mar 2008 | A1 |
20080103553 | Penner et al. | May 2008 | A1 |
20080108915 | Penner | May 2008 | A1 |
20080171941 | Huelskamp et al. | Jul 2008 | A1 |
20080195002 | Thompson et al. | Aug 2008 | A1 |
20080228094 | Audet et al. | Sep 2008 | A1 |
20080243007 | Liao et al. | Oct 2008 | A1 |
20080243210 | Doron et al. | Oct 2008 | A1 |
20090312650 | Maile et al. | Dec 2009 | A1 |
20090326609 | Doron | Dec 2009 | A1 |
20100023091 | Stahmann et al. | Jan 2010 | A1 |
20100106028 | Penner et al. | Apr 2010 | A1 |
20100274302 | Armstrong et al. | Oct 2010 | A1 |
20110160804 | Penner | Jun 2011 | A1 |
20130218251 | Penner | Aug 2013 | A1 |
20130226259 | Penner | Aug 2013 | A1 |
20130238044 | Penner | Sep 2013 | A1 |
Number | Date | Country |
---|---|---|
0 499 939 | Aug 1992 | EP |
0 928 598 | Dec 1998 | EP |
1962557 | Aug 2008 | EP |
59-164035 | Sep 1984 | JP |
05-023323 | Feb 1993 | JP |
08-331065 | Dec 1996 | JP |
09-147284 | Jun 1997 | JP |
10-093477 | Apr 1998 | JP |
10-505529 | Jun 1998 | JP |
2002-515807 | May 2002 | JP |
2002515807 | May 2002 | JP |
2004-041724 | Feb 2004 | JP |
2004041724 | Feb 2004 | JP |
2004-511313 | Apr 2004 | JP |
2004-537347 | Dec 2004 | JP |
2005-521528 | Jul 2005 | JP |
WO 8802250 | Apr 1988 | WO |
WO 9626673 | Sep 1996 | WO |
WO 97-33513 | Sep 1997 | WO |
WO 9843338 | Oct 1998 | WO |
WO 9843701 | Oct 1998 | WO |
WO 98-52142 | Nov 1998 | WO |
WO 99-04287 | Jan 1999 | WO |
WO 9934453 | Jul 1999 | WO |
WO 0047109 | Aug 2000 | WO |
WO 0128627 | Apr 2001 | WO |
WO 0174278 | Oct 2001 | WO |
WO 0176687 | Oct 2001 | WO |
WO 0197907 | Dec 2001 | WO |
WO 0203347 | Jan 2002 | WO |
WO 0232502 | Apr 2002 | WO |
WO 02089904 | Nov 2002 | WO |
WO03002243 | Jan 2003 | WO |
WO 03043688 | May 2003 | WO |
WO 03096889 | Nov 2003 | WO |
WO 2004089465 | Oct 2004 | WO |
WO 2005009535 | Feb 2005 | WO |
WO 2005053786 | Jun 2005 | WO |
WO 2005099816 | Oct 2005 | WO |
WO 2006017615 | Feb 2006 | WO |
WO 2006034183 | Mar 2006 | WO |
WO 2006060668 | Jun 2006 | WO |
WO 2006126401 | Nov 2006 | WO |
WO 2007070794 | Jun 2007 | WO |
WO 2007080487 | Jul 2007 | WO |
WO 2007127696 | Nov 2007 | WO |
WO 2008118908 | Oct 2008 | WO |
WO 2010062538 | Jun 2010 | WO |
Entry |
---|
U.S. Appl. No. 12/427,312, Non-Final Office Action dated Dec. 4, 2013, 14 pages. |
Harrison et al., “A Low-Power Low-Noise CMOS Amplifier for Neural Recording Applications,” IEEE Journal of Solid-State Circuits 38(6):958-965, Jun. 2003. |
IEEE Transactions on Biomedical Engineering, vol. 42, No. 5, May 1995, Title: Data Transmission from an Implantable Biotelemeter by Load-Shift Keying Using Circuit Configuration Modulator, by Zhengnian Tang, Brian Smith, John H. Schild, and P. Hunter Peckham, pp. 524-528. |
Ishiwara et al., “Current Status and Prospects of FET-Type Ferroelectric Memories,” Journal of Semiconductor Technology and Science 1(1): 1-14, Mar. 2001. |
Neurosurgery Clinics of North America vol. 4, No. 4, Oct. 1993, Hydrocephalus, Title: The Treatment of Hydrocephalus by Paul M. Kanev, MD, and T.S. Park, MD., pp. 611-619. |
Neurosurgery Clinics of North America, vol. 4, No. 4, Oct. 1993, Hydrocephalus, Title: Complications in Ventricular Cerebrospinal Fluid Shunting by Jeffrey P. Blount, MD, John A. Campbell, MD, and Stephen J. Haines, MD, pp. 633-656. |
Neurosurgery Update II Vascular, Spinal, Pediatric, and Functional Neurosurgery, Published by McGraw-Hill, Inc., 1991, Editors Robert H. Wilkins, M.D., and Setti S. Rengachary, M.D., Title Shunt Complications by R. Michael Scott, pp. 300-319. |
Neurosurgery, vol. 34, No. 5, May 1994, Concepts and Innovations, Title: A New Ventricular Catheter for the Prevention and Treatment of Proximal Obstruction in Cerebrospinal Fluid Shunts, by Enrique C.G. Ventureyra, M.D., F.R.C.S.(C)., F.A.C.S., Michael J. Higgins, M.D., pp. 924-926. |
Neurosurgery, vol. 34, No. 6, Jun. 1994, Rapid Communication, Title: The Use of the Codman-Medos Programmable Hakim Valve in the Management of Patients with Hydroceplhalus: Illustrative Cases, by Peter McL. Black, M.D., Ph.D., Rodolfo Hakim, M.D., Nancy Olsen Bailey, R.N., B.S.N., M.B.A., pp. 1110-1113. |
Pediatric Neurosurgery 2nd Edition, Surgery of the Developing Nervous System, Published by W.B. Saunders Company Harcourt Brace Jovanovich, Inc., 1989. Title: Treatment of Hydrocephalus by Harold L. Rekate, M.D.; Ventricular Shunts: Complications and Results by Robert L. McLaurin, M.D.; pp. 200-229. |
International Search Report and Written Opinion issued in PCT/US2009/062019, 14 pages. |
Extended European Search Report issued in EP 10184174, mailed Dec. 7, 2010. |
Number | Date | Country | |
---|---|---|---|
20140073972 A1 | Mar 2014 | US |
Number | Date | Country | |
---|---|---|---|
61108635 | Oct 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12605579 | Oct 2009 | US |
Child | 14088425 | US |